355 related articles for article (PubMed ID: 25860328)
1. The cost of ipilimumab toxicity: a single-centre analysis.
Yousaf N; Davidson M; Goode E; Thomas C; Hung R; Gore M; Larkin J
Melanoma Res; 2015 Jun; 25(3):259-64. PubMed ID: 25860328
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting.
Guglieri-López B; Pérez-Pitarch A; Porta Oltra B; Ferriols-Lisart F; Royo-Peiró Á; Climente-Martí M
Anticancer Drugs; 2016 Aug; 27(7):679-84. PubMed ID: 27058705
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
[TBL] [Abstract][Full Text] [Related]
8. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
[TBL] [Abstract][Full Text] [Related]
9. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
Eigentler TK; Schlaak M; Hassel JC; Loquai C; Stoffels I; Gutzmer R; Pätzold S; Mohr P; Keller U; Starz H; Ulrich J; Tsianakas A; Kähler K; Hauschild A; Janssen E; Schuler-Thurner B; Weide B; Garbe C
J Immunother; 2014 Sep; 37(7):374-81. PubMed ID: 25075567
[TBL] [Abstract][Full Text] [Related]
11. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
Johnson DB; Friedman DL; Berry E; Decker I; Ye F; Zhao S; Morgans AK; Puzanov I; Sosman JA; Lovly CM
Cancer Immunol Res; 2015 May; 3(5):464-9. PubMed ID: 25649350
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab-induced colitis on FDG PET/CT.
Lyall A; Vargas HA; Carvajal RD; Ulaner G
Clin Nucl Med; 2012 Jun; 37(6):629-30. PubMed ID: 22614208
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
[TBL] [Abstract][Full Text] [Related]
14. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.
Bernardo SG; Moskalenko M; Pan M; Shah S; Sidhu HK; Sicular S; Harcharik S; Chang R; Friedlander P; Saenger YM
Melanoma Res; 2013 Feb; 23(1):47-54. PubMed ID: 23262440
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab-induced colitis: a rare but serious side effect.
Hinds AM; Ahmad DS; Muenster JE; Berg ZM; Lopez KT; Holly JS; Matteson-Kome ML; Bechtold ML
Endoscopy; 2014; 46 Suppl 1 UCTN():E308-9. PubMed ID: 25058826
[No Abstract] [Full Text] [Related]
16. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
Weber JS; Dummer R; de Pril V; Lebbé C; Hodi FS;
Cancer; 2013 May; 119(9):1675-82. PubMed ID: 23400564
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab.
Uslu U; Agaimy A; Hundorfean G; Harrer T; Schuler G; Heinzerling L
J Immunother; 2015 Jun; 38(5):212-5. PubMed ID: 25962110
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
19. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Margolin K; Ernstoff MS; Hamid O; Lawrence D; McDermott D; Puzanov I; Wolchok JD; Clark JI; Sznol M; Logan TF; Richards J; Michener T; Balogh A; Heller KN; Hodi FS
Lancet Oncol; 2012 May; 13(5):459-65. PubMed ID: 22456429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
